Stronger anti-tumor activity was achieved when the combination started from the beginning (e.g. from the first treatment cycle) (Figure 4G) compared with combination that started after progression to CEA-TCB monotherapy treatment (Figure 4H). This evidence concerns the gene CEACAM5 and neoplasm.